About Engitix Therapeutics

Engitix targets the extracellular matrix, the structural scaffolding supporting every cell in human tissue. In chronic diseases like fibrosis and cancer, this architecture transforms into a disease driver, becoming thicker, stiffer, and amplifying harmful signals. The company uses the world's first patient-centric ECM discovery platform to decode these mechanisms and develop transformative therapies. The platform combines one of the largest human ECM bioarchives with proprietary 3D cell culture models and AI-driven analytics to identify novel drug targets. This enables more accurate prediction of therapeutic efficacy and reduces clinical failure risk. The pipeline targets advanced fibrosis, inflammation, and solid tumours.